Roy Fleischmann News Today

Results demonstrated comparable safety, immunogenicity, and pharmacokinetics between adalimumab-afzb and the reference product.

The drug, adalimumab-afzb (Abrilada), is the second adalimumab biosimilar approved with interchangeability status. It will be available later this month.

Experts say that these negative findings do not imply that other VNS therapies will be unsuccessful.

Randomized trial gives hopes for novel treatment a cold shower

The rheumatology month in review features studies reporting increased depression rates among patients with autoimmune disease, interventions designed to decrease chronic pain symptoms in fibromyalgia, and highlights from EULAR 2023.

Results found all clinical and patient-reported responses were statistically better with upadacitinib plus methotrexate compared with adalimumab plus methotrexate, although both treatments were effective.

Two phase 3 trials of the once-monthly SEL-212 in refractory gout achieved and maintained serum uric acid

After 12 weeks of treatment, the median sUA levels of patients with gout were reduced from 8.6 mg/dL to 3.6 mg/dL in the AR882 75 mg cohort and 5.0 mg/dL in the AR882 50 mg group.

Results of a phase 3 trial in Chinese patients with systemic lupus erythematosus showed a significantly greater response rate with telitacicept, compared with placebo.

Upadacitinib 15 mg once daily had a better clinical response compared to adalimumab 40 mg every other week at 12 weeks in 3-year follow-up data among patients with rheumatoid arthritis.